← К результатам

VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol.

Hooper AJ, Tang XL, Burnett JR

Expert opinion on investigational drugs, 33(8): 753-756 PMID 38878270 DOI 10.1080/13543784.2024.2369747